Navigation Links
Piedmont Pharmaceuticals Secures $8.5 Million Investment
Date:11/12/2007

GREENSBORO, N.C., Nov. 12 /PRNewswire/ -- Piedmont Pharmaceuticals LLC, a specialty pharmaceutical company focused on parasitology and drug delivery systems for human and companion animal use, has secured $8.5 million in Series B financing from CM Capital Investments of Brisbane, Australia, and other accredited investors.

This funding will help advance development of Piedmont Pharmaceuticals' pipeline, particularly the U.S. Phase III clinical trials of its unique patented, insecticide-free head lice treatment. Through licensees abroad, this pediculicide rinse is already approved and is the market leader in the United Kingdom and Ireland (under the name Full Marks Solution(R)) and gaining market share in Canada (as RESULTZ(R)). While no timetable has been set, Piedmont Pharmaceuticals anticipates expanding distribution of the product through licensees in the European, Asian and Australasian markets.

"We are very pleased to be working with an investment company of CM Capital's geographical scope and expertise," said Roland Johnson, CEO and Chairman of the Board for Piedmont Pharmaceuticals. "We believe this investment, the first major institutional backing for Piedmont Pharmaceuticals, sends a strong signal about our company's progress and potential. As we move our pediculicide compound through Phase III trials and continue developing the rest of our portfolio, we welcome the guidance and global connections that CM Capital can offer."

"CM Capital invests in companies that can achieve market leadership positions in their respective market sectors," said Andy Jane, partner at CM Capital Investments. "With its talented and proven team of industry veterans, Piedmont Pharmaceuticals has an excellent opportunity to succeed in both the human and animal health markets in the U.S. and beyond."

Members of Piedmont Pharmaceuticals' team have worked together in the health care industry for more than 20 years, bringing more than 11 products to market. In addition to the pediculicide rinse, Piedmont Pharmaceuticals' pipeline includes a topical treatment for otitis media in humans and a chewable drug delivery platform for companion animals, both in preclinical stages.

About Piedmont Pharmaceuticals:

Piedmont Pharmaceuticals LLC is a Greensboro, N.C. - based specialty pharmaceutical company focused on human and animal health therapeutics in such select areas as parasitology and the treatment of infection. The company's currently commercialized products and advanced development program leverage unique modes of action and proprietary delivery technologies. Piedmont Pharmaceuticals develops new formulations, uses and delivery vehicles for known active pharmaceutical compounds for human and companion animal health markets.

About CM Capital Investments:

CM Capital is headquartered in Brisbane, Australia and is one of the pioneers of the Australian Venture Capital industry. They have over $270m under management and are one of Australia's leading early stage VC fund managers. Their investor base consists of some of Australia's leading superannuation funds and financial institutions. CM Capital is staffed by industry professionals with strong operational expertise and focuses its investments in the areas of life sciences, biotechnology and telecommunications/IT.

Note: Full Marks Solution(R) is a registered trademark of SSL International PLC, a licensee of Piedmont Pharmaceuticals.


'/>"/>
SOURCE Piedmont Pharmaceuticals LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Fairfax, VA (PRWEB) , ... March 28, 2017 , ... ... T. Still, MHA, FRBMA, has begun to serve as its new executive director. Mr. ... and the Executive Search Committee. , “Bob, as he is known to our ...
(Date:3/28/2017)... Vilnius, Lithuania (PRWEB) , ... March 28, 2017 ... ... identification technologies, today announced the release of two biometric time and attendance tracking ... Bio Attendance 4.0 software. NCheck Cloud Bio Attendance uses biometric face recognition ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Executives, Staff & Clients of MGE: Management ... Toys for Tots Literacy Campaign at their Semi-Annual Graduation and Fundraiser Event at MGE’s ... U.S. ranks at number 14 internationally in literacy. Statistically, a direct relation can be ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric ... Inc. is thrilled to offer the recently FDA-approved Obalon Balloon System to his ... to SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... Silicon ... is proud to announce a new blog post about women’s hair loss. Although hair ... from hair loss as they age. Menopause or genetics can be two reasons a ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... STUTTGART, Germany , March 27, 2017 /PRNewswire/ ... provide over 7,000 attendees and more than 600 ... learn, and discover opportunities and solutions that will ... - 6 April 2017 at the Messe Stuttgart, ... is the preeminent medical technology platform showcasing the ...
(Date:3/27/2017)... British Columbia, March 27, 2017  Sophiris Bio ... or "Sophiris"), a clinical late-stage biopharmaceutical company developing ... urological diseases, today reported fourth quarter and full ... Key Corporate Highlights: ... Localized Prostate Cancer. During 2016, the Company reported ...
(Date:3/27/2017)... 27, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus ... Invictus MD is pleased to announce it has received ... on the TSX Venture Exchange.  Receiving ... year of significant achievements for Invictus-MD. Some of which ... at AB Laboratories Inc. ("AB Labs"), a Licensed Producer ...
Breaking Medicine Technology: